{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-24-004239","form_type":"8-K","ticker":"ZOMDF","cik":"0001684144","company_name":"Zomedica Corp.","filed_at":"2024-04-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.576786+00:00","generated_at":"2026-06-04T02:20:43.560188+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Zomedica reports record FY 2023 revenue $25.2M (+33% YoY); net loss $34.5M; guides FY 2024 revenue $31-35M","bullets":["Q4 2023 revenue $7.3M (+19% YoY); full-year revenue $25.2M vs $18.9M in 2022.","Gross margin 69% for both Q4 and full year 2023; consumable revenue grew 41% to $16.4M.","Net loss $34.5M ($0.035 per share) vs $17.0M ($0.017) in 2022; adjusted non-GAAP EBITDA loss $12.8M.","Cash and securities $100.5M as of Dec 31, 2023; operating cash burn adjusted for one-time items ~$2.6M in Q4.","FY 2024 revenue guidance $31-35M (up to 40% YoY); growth driven by recent product launches and acquisitions."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-24-004239","json":"https://secwatch.observer/filing/0001654954-24-004239.json","markdown":"https://secwatch.observer/filing/0001654954-24-004239.md","text":"https://secwatch.observer/filing/0001654954-24-004239.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1684144/000165495424004239/0001654954-24-004239-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1684144/000165495424004239/zom_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T02:20:43.560188+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2963e34e9938583c37e31711cf6f7778fe63cfc9","claim":"Zomedica Corp. reported the fourth quarter ended December 31, 2023 results: revenue $7.3 million.","evidence_excerpt":"Revenue for the fourth quarter of 2023 grew 19% to $7.3 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1684144/000165495424004239/0001654954-24-004239-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2023"},{"label":"Revenue","value":"$7.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"890a48602a3e6cd40605c5739433f59c236a4470","claim":"Zomedica Corp. reported the year ended December 31, 2023 results: revenue $25.2 million.","evidence_excerpt":"X-99.1 2 zom_ex991.htm PRESS RELEASE zom_ex991.htm EXHIBIT 99.1 Zomedica Reports Record Revenue of $7.3 Million for the Fourth Quarter and $25.2 Million for the Full Year 2023, Reflecting 33% Annual Growth; 69% Gross Margin and $100.5 Million in Liquidity ANN ARBOR, MI / ACCESSWIRE / April 1, 2024 / Zomedica Corp.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1684144/000165495424004239/0001654954-24-004239-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Revenue","value":"$25.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"ab556add369cbde631003f009e7e9b29eb1676ec","claim":"Zomedica Corp. reported full year 2024 results: revenue $31 to $35 million. Guidance reaffirmed.","evidence_excerpt":"Zomedica continues to expect full year revenue in the range of $31 to $35 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1684144/000165495424004239/0001654954-24-004239-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2024"},{"label":"Revenue","value":"$31 to $35 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}